Weave (NYSE: WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced an integration with Practice Fusion, a ...

For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: + 46 (0) 8 510 530 00 [email protected] hellocare.ai, a leader in AI-assisted ...

Linvoseltamab is a bispecific antibody targeting B-cell maturation antigen ... to address therapeutic challenges and improve patient outcomes. The FDA accepted Regeneron’s BLA resubmission for ...

In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies. Xencor's ...

In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies.

which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and ...

“CD28 co-stimulatory bispecific antibodies are designed to boost T cell-mediated tumor killing and overcome T cell exhaustion in the solid tumor microenvironment. In preclinical studies, RNDO-564 ...